DHI — D.R. Horton, Inc.

The tape is unambiguously negative as of 2026-09-13: DHI is down 10.51% over 3 months, 5.44% over 1 month, 3.4% over 1 week, and sits below its 20-, 50- and 200-day moving averages while printing an RSI(14) of 40.12. The fundamental trigger was the late-July 2026 cut to full-year revenue guidance ($32.5-33B vs. prior consensus), blamed on affordability, soft consumer sentiment and elevated mortgage rates, plus Q3 FY26 EPS of $3.18 versus $3.36 a year earlier with gross margin (23.3%) down ~320bps from the prior-year quarter. Sell-side has settled on a Hold consensus (25 holds vs. 23 buys, 3 sells, 2 strong buys) even though the $160 consensus price target implies meaningful upside — a classic 'cheap but no reason to hurry' stance. Note this is grinding bearishness, not capitulation: RSI has not broken 30 and the stock has not made a new 52-week low.

This is a cyclical deceleration that is now showing early signs of bottoming, not a structural collapse. Revenue went from a $10.50B peak in Q4 FY23 and $10.00B in Q4 FY24 to year-over-year declines of -9.5% (Q1 FY26, $6.89B vs. $7.61B) and -2.3% (Q2 FY26, $7.56B vs. $7.73B), then flattened to +0.02% in Q3 FY26 ($9.227B vs. $9.226B) — the YoY gap has closed for three straight quarters. Margins tell the same story in sharper relief: operating margin fell from 18.9% in Q4 FY23 and 17.7% in Q3 FY24 to a trough of 10.58-10.59% in Q1/Q2 FY26 (roughly 800bps of compression), then rebounded to 13.29% in Q3 FY26. Gross margin went from 26.5% in Q3 FY24 to 23.3% in Q3 FY26, but the last three quarters have been stable-to-improving (23.16% → 22.53% → 23.26%), suggesting the incentive/buydown burden may be peaking. EPS traced a clean arc: peak $4.10 in Q3 FY24, trough $2.03 in Q1 FY26, back to $3.18 in Q3 FY26 — still -5.4% YoY but up 42% sequentially. Cash generation has not broken: TTM operating cash flow through 2026-06-30 was $3.35B versus $2.91B in the comparable prior-year TTM, and FCF was $3.18B, an ~8.2% FCF yield. Verdict: decelerating trend that is inflecting, with the trough roughly two quarters behind us in margin terms — but no confirmed recovery in volume or pricing yet.

Fair, with a mechanically distorted headline. As of 2026-09-13, DHI's trailing P/E was 13.1x against a 5-year average of 9.36x — a ~40% premium that sounds alarming until you note the 5-year average was set while EPS sat at a cyclical peak (~$14.36 in FY24); applying a peak-cycle multiple to trough-cycle earnings double-penalizes. Forward P/E on next-FY consensus EPS of $10.47 is ~13.2x, i.e. the market is paying a market-ish multiple for zero expected growth (the PEG ratio of -0.817 is meaningless here precisely because growth is negative). The cross-checks are friendlier: P/S of 1.16x is slightly BELOW the 5-year average of 1.21x, price/book of 1.66x pairs with a 14.8% ROE and 10.1% ROIC, and TTM FCF of $3.18B on a $38.6B market cap is an ~8.2% free-cash-flow yield. Net: not cheap on earnings, not expensive on sales, assets or cash flow. This is a fair-value stock with a trough-inflated P/E, and the deterministic score's 'Rich vs. its own history' label is being driven entirely by that P/E artifact.

At $137.89, the market is capitalizing next-FY consensus EPS of $10.47 at 13.2x — and critically, that consensus embeds no recovery: next-FY revenue of $32.77B is actually BELOW the ~$33B midpoint of current FY26 guidance. So the stock is not pricing in a housing rebound; it is pricing in stagnation and applying a slightly-above-history multiple to it. That cuts both ways. If mortgage rates ease and FY27-28 EPS re-rates toward $12-plus, the multiple on today's price compresses to ~11.5x and the stock looks cheap in hindsight. If EPS instead breaks below $10 (another guidance cut on October 29, deeper buydowns, tariff-driven cost inflation), 13x on $9.50 is ~$124, and the stock has downside toward the 52-week low of $131.75. The asymmetry tilts modestly positive but the catalyst is macro (rates), not company-specific execution — which is exactly why I would not pay up here.

As of 2026-09-13, the technical picture is a clean, unremarkable downtrend with no oversold trigger. RSI(14) stood at 40.12 — weak, but genuinely NOT oversold; there has been no RSI sub-30 washout, so there is no classic capitulation-bounce setup. Price was 4.85% below the 20-day SMA (implied ~$144.9), 6.40% below the 50-day (~$147.3) and 7.94% below the 200-day (~$149.8) — note how tightly those three averages are clustered in the $145-150 zone, which is also right around my estimate of fair value. That clustering means the entire $145-150 band is now overhead resistance. Entry-timing read: no trend reversal signal exists yet; the first real evidence of a change would be a reclaim of the 50-day around $147, and a push back above the 200-day near $150 would confirm it. Until then, buying here is catching a falling knife on a macro call, not a technical one.

• Mortgage rates and the Fed path — the single biggest swing factor. Periodic soft labor prints (like the weak July jobs report) spark brief rallies on rate-cut hopes, but as of 2026-09-13 mortgage rates remain high enough to strain buyer purchasing power and DHI is explicitly citing this in guidance.
• Affordability and the structural cost of incentives — heavy mortgage rate buydowns and shrinking square footage preserve order volume but cap gross margin at ~23% versus 26-27% in FY24; this looks semifunctional rather than temporary until rates fall.
• Construction cost inflation and tariff exposure on lumber/materials — sticky input costs are compressing both gross and operating margin independent of the rate cycle.
• Structural US housing undersupply — a genuine multi-year tailwind that underwrites long-term demand, and DHI's skew toward entry-level/Express product positions it to take share when affordability improves.
• Existing-home supply and the mortgage lock-in effect — as sellers eventually list, competitive resale inventory rises, which could blunt new-home pricing even if rates fall.
• Homebuilder beta and sector rotation — DHI's 1.371 beta means it amplifies both housing-sector drawdowns and rate-cut-driven rallies; the stock will likely move on macro headlines before it moves on company fundamentals.

• Q4 and full-year FY26 earnings on Wednesday, October 29, 2026 (pre-market) — the single most important near-term event. The initial FY27 outlook, autumn selling-season commentary, and any evidence that gross margin has inflected (Q3 FY26's 23.26% was the best since Q4 FY25) will drive the next leg.
• Federal Reserve rate cuts / falling mortgage rates — a direct affordability tailwind that would raise absorption and let DHI reduce incentive spend, lifting both volume and margin simultaneously.
• Continued large-scale capital return — stockholders' equity fell from $25.31B (2024-09-30) to $23.82B (2026-06-30) despite roughly $5.7B of net income over that span, implying substantial buybacks plus the 1.23% dividend; a meaningful shareholder yield at these prices.
• Margin-trough confirmation — three consecutive quarters of stable-to-rising gross margin (23.16% → 22.53% → 23.26%) would, if it holds, be the signal that the earnings estimate floor has been set.
• Sector rotation into rate-sensitive cyclicals if the labor market softens enough to force faster cuts — historically the fastest way a homebuilder re-rates.

• Mortgage rates staying elevated into FY27 — would prolong the affordability crunch, force deeper incentive usage and push gross margin below the 22.5% Q2 FY26 level, invalidating the trough thesis.
• Another guidance cut on October 29, 2026 — consensus next-FY EPS of $10.47 already assumes no growth; if management guides below that, the 13.2x forward multiple has no cushion, especially versus the 9.36x 5-year average.
• Inventory and land impairment risk — $34.6B of current assets (mostly land, WIP and finished homes) against $23.8B of equity; a prolonged downturn could force write-downs that the strong current ratio (9.84) does not protect against.
• Tariff and materials cost inflation — an exogenous cost shock that hits margin regardless of demand, and one the company has already cited as a Q3 FY26 pressure.
• Valuation asymmetry — a 13.1x trailing P/E versus a 9.36x 5-year average means the multiple, not just the earnings, can compress; if earnings fall 10% and the multiple normalizes to 11x, that is roughly $115-120.
• Negative growth momentum in the analyst model itself — a negative PEG (-0.817) and a next-FY revenue estimate ($32.77B) below current-year guidance means the sell-side model is not yet calling a turn; being early on a cyclical call is expensive.
• High beta (1.371) amplifies any broad market or housing-sector drawdown, so even a correct company-level thesis can produce a painful paper loss.

DHI is a best-in-class, cash-generative market leader sitting in a real but ordinary housing downcycle — not a broken business. The balance sheet is immaculate (0.30 debt/equity, 9.84 current ratio, net debt of roughly $3.7B against $23.8B of equity), it throws off an ~8.2% free-cash-flow yield, and the operating margin trajectory (10.6% trough in Q1/Q2 FY26 to 13.3% in Q3 FY26) plus flattening revenue YoY suggest the worst of the compression may be behind it. But at 13.2x flat forward earnings versus a 9.36x five-year average, with consensus modeling zero FY27 growth and no confirmed volume recovery, there is no margin of safety being offered — you are paying a fair-to-full price for an unproven inflection whose catalyst (rate cuts) is entirely outside the company's control. This is a reasonable long-term hold and a decent watchlist name, not a compelling buy at $137.89; I would want either a pullback toward the $125-130 zone or hard evidence of a margin bottom on October 29 before getting constructive.

Blended four-way intrinsic estimate as of 2026-09-13, weighted toward normalized earnings: (1) mid-cycle EPS of ~$12.43 (midpoint of FY24's peak $14.36 and the current ~$10.50 run-rate) at a justified 11.5x mid-cycle multiple = $143; (2) TTM FCF of $3.18B capitalized at an 8% fair free-cash-flow yield = $142/share; (3) 1.75x price/book on BVPS of $85.16 (equity $23.82B / ~280M shares) = $149; (4) 14x forward P/E on next-FY consensus EPS of $10.47 = $147. A 40/20/20/20 weighting of those gives ~$145, which sits just above the current $137.89 and inside the tightly clustered $145-150 SMA20/50/200 resistance band — i.e. modest upside to fair value, no valuation cushion, consistent with a Neutral lean.